Literature DB >> 19244517

Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease.

Prasad R Joshi1, Nan-Ping Wu, Véronique M André, Damian M Cummings, Carlos Cepeda, John A Joyce, Jeffrey B Carroll, Blair R Leavitt, Michael R Hayden, Michael S Levine, Nigel S Bamford.   

Abstract

Huntington disease is a genetic neurodegenerative disorder that produces motor, neuropsychiatric, and cognitive deficits and is caused by an abnormal expansion of the CAG tract in the huntingtin (htt) gene. In humans, mutated htt induces a preferential loss of medium spiny neurons in the striatum and, to a lesser extent, a loss of cortical neurons as the disease progresses. The mechanisms causing these degenerative changes remain unclear, but they may involve synaptic dysregulation. We examined the activity of the corticostriatal pathway using a combination of electrophysiological and optical imaging approaches in brain slices and acutely dissociated neurons from the YAC128 mouse model of Huntington disease. The results demonstrated biphasic age-dependent changes in corticostriatal function. At 1 month, before the behavioral phenotype develops, synaptic currents and glutamate release were increased. At 7 and 12 months, after the development of the behavioral phenotype, evoked synaptic currents were reduced. Glutamate release was decreased by 7 months and was markedly reduced by 12 months. These age-dependent alterations in corticostriatal activity were paralleled by a decrease in dopamine D(2) receptor modulation of the presynaptic terminal. Together, these findings point to dynamic alterations at the corticostriatal pathway and emphasize that therapies directed toward preventing or alleviating symptoms need to be specifically designed depending on the stage of disease progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19244517      PMCID: PMC2670193          DOI: 10.1523/JNEUROSCI.5687-08.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  66 in total

1.  Imaging synaptic activity in intact brain and slices with FM1-43 in C. elegans, lamprey, and rat.

Authors:  A R Kay; A Alfonso; S Alford; H T Cline; A M Holgado; B Sakmann; V A Snitsarev; T P Stricker; M Takahashi; L G Wu
Journal:  Neuron       Date:  1999-12       Impact factor: 17.173

2.  Visualization of changes in presynaptic function during long-term synaptic plasticity.

Authors:  S S Zakharenko; L Zablow; S A Siegelbaum
Journal:  Nat Neurosci       Date:  2001-07       Impact factor: 24.884

3.  Sub-second changes in accumbal dopamine during sexual behavior in male rats.

Authors:  D L Robinson; P E Phillips; E A Budygin; B J Trafton; P A Garris; R M Wightman
Journal:  Neuroreport       Date:  2001-08-08       Impact factor: 1.837

4.  Differential modulation of AMPA receptors by cyclothiazide in two types of striatal neurons.

Authors:  V S Vorobjev; I N Sharonova; H L Haas; O A Sergeeva
Journal:  Eur J Neurosci       Date:  2000-08       Impact factor: 3.386

5.  Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease.

Authors:  M S Levine; G J Klapstein; A Koppel; E Gruen; C Cepeda; M E Vargas; E S Jokel; E M Carpenter; H Zanjani; R S Hurst; A Efstratiadis; S Zeitlin; M F Chesselet
Journal:  J Neurosci Res       Date:  1999-11-15       Impact factor: 4.164

6.  Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.

Authors:  M Suzuki; T J Desmond; R L Albin; K A Frey
Journal:  Synapse       Date:  2001-09-15       Impact factor: 2.562

7.  Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores.

Authors:  Y Schmitz; C J Lee; C Schmauss; F Gonon; D Sulzer
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

8.  Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease.

Authors:  M Turmaine; A Raza; A Mahal; L Mangiarini; G P Bates; S W Davies
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

9.  Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease.

Authors:  E Sapp; J Penney; A Young; N Aronin; J P Vonsattel; M DiFiglia
Journal:  J Neuropathol Exp Neurol       Date:  1999-02       Impact factor: 3.685

10.  Age-related changes in the capacity, rate, and modulation of dopamine uptake within the striatum and nucleus accumbens of Fischer 344 rats: an in vivo electrochemical study.

Authors:  M A Hebert; G A Gerhardt
Journal:  J Pharmacol Exp Ther       Date:  1999-02       Impact factor: 4.030

View more
  83 in total

1.  A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Authors:  Damian M Cummings; Yasaman Alaghband; Miriam A Hickey; Prasad R Joshi; S Candice Hong; Chunni Zhu; Timothy K Ando; Véronique M André; Carlos Cepeda; Joseph B Watson; Michael S Levine
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

2.  Differential electrophysiological changes in striatal output neurons in Huntington's disease.

Authors:  Véronique M André; Carlos Cepeda; Yvette E Fisher; My Huynh; Nora Bardakjian; Sumedha Singh; X William Yang; Michael S Levine
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

3.  The Huntington's disease mutation impairs Huntingtin's role in the transport of NF-κB from the synapse to the nucleus.

Authors:  Edoardo Marcora; Mary B Kennedy
Journal:  Hum Mol Genet       Date:  2010-08-25       Impact factor: 6.150

4.  Cortical Network Dynamics Is Altered in Mouse Models of Huntington's Disease.

Authors:  Elissa J Donzis; Ana María Estrada-Sánchez; Tim Indersmitten; Katerina Oikonomou; Conny H Tran; Catherine Wang; Shahrzad Latifi; Peyman Golshani; Carlos Cepeda; Michael S Levine
Journal:  Cereb Cortex       Date:  2020-04-14       Impact factor: 5.357

Review 5.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

6.  Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background.

Authors:  Melissa K Strong; Amber L Southwell; Jennifer M Yonan; Michael R Hayden; Grant R Macgregor; Leslie M Thompson; Oswald Steward
Journal:  J Huntingtons Dis       Date:  2012

7.  Imaging presynaptic exocytosis in corticostriatal slices.

Authors:  Minerva Y Wong; David Sulzer; Nigel S Bamford
Journal:  Methods Mol Biol       Date:  2011

Review 8.  The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Authors:  Ravi Chopra; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

9.  Overinhibition of corticostriatal activity following prenatal cocaine exposure.

Authors:  Wengang Wang; Ioana Nitulescu; Justin S Lewis; Julia C Lemos; Ian J Bamford; Natasza M Posielski; Granville P Storey; Paul E M Phillips; Nigel S Bamford
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

10.  Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.

Authors:  Carlos Cepeda; Laurie Galvan; Sandra M Holley; Shilpa P Rao; Véronique M André; Elian P Botelho; Jane Y Chen; Joseph B Watson; Karl Deisseroth; Michael S Levine
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.